Cobra Venom Factor-induced complement depletion protects against lung ischemia reperfusion injury through alleviating blood-air barrier damage

Chang Haihua1, Wang Wei1, Huang Kun1, Liao Yuanli1 & Lin Fei2

The purpose of this study was to study whether complement depletion induced by pretreatment with Cobra Venom Factor (CVF) could protect against lung ischemia reperfusion injury (LIRI) in a rat model and explore its molecular mechanisms. Adult Sprague-Dawley rats were randomly assigned to five groups (n = 6): Control group, Sham-operated group, I/R group, CVF group, I/R + CVF group. CVF (50 μg/kg) was injected through the tail vein 24 h before anesthesia. Lung ischemia reperfusion (I/R) was induced by clamping the left hilus pulmonis for 60 minutes followed by 4 hours of reperfusion. Measurement of complement activity, pathohistological lung injury score, inflammatory mediators, pulmonary permeability, pulmonary edema, integrity of tight junction and blood-air barrier were performed. The results showed that pretreatment with CVF significantly reduced complement activity in plasma and BALF. Evaluation in histomorphology showed that complement depletion induced by CVF significantly alleviated the damage of lung tissues and inhibited inflammatory response in lung tissues and BALF. Furthermore, CVF pretreatment had the function of ameliorating pulmonary permeability and preserving integrity of tight junctions in IR condition. In conclusion, our results indicated that complement depletion induced by CVF could inhibit I/R-induced inflammatory response and alleviate lung I/R injury. The mechanisms of its protective effects might be ameliorated blood-air barrier damage.

Ischemia-reperfusion (I/R) injury is a serious clinical event which can take place in diverse conditions, such as organ transplantation, shock, cardiac arrest, thoracic surgery and multiple trauma1,2. Owing to the unique dual blood supply systems and physiological features, the lung is vulnerable to I/R injury3,4. The pathogenesis of lung ischemia reperfusion injury (LIRI) is complex and remains unclear. Therefore, more study is needed to elucidate the pathological mechanisms of LIRI and explore effective treatment methods.

Some studies confirm that lung I/R could induce sterile inflammatory eruption by activating the innate immune response5–7. The immune inflammatory reaction during lung I/R initiates by attracting inflammatory cells, such as lymphocytes, neutrophils, macrophages and releasing pro-inflammatory factors8. The complement system plays a pivotal role in activating the innate immune system. However, excessive complement activation and immune activation could lead to severe tissue injury9,10. Therefore, the uncontrollable complement activation is considered to be responsible for the pathogenesis mechanism of acute lung injury (ALI) induced by I/R. Inhibition of excessive complement activation might be a possible way to alleviate the tissue injury caused by I/R11,12.

Cobra Venom Factor (CVF) is a non-toxic protein purified from cobra venom. It is a structural analogue of complement component C3 and has the function of complement activation13. Treatment with CVF could deplete complement protein and achieve the desired anti-complement effect through continuously activating complement component C3 for a long time14. Several studies have shown that complement depletion caused by treatment of CVF plays a beneficial effect in the pathological process of transplantation15–17. Thus, the CVF treatment could be a possible therapeutic measure for lung I/R injury. But, as far as we know, there are few studies that

1Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. 2Department of Emergency, the First Affiliated Hospital of Guangxi Medical University, Nanning, China. Correspondence and requests for materials should be addressed to L.F. (email: flylin0208@163.com)
have been designed to explore its effects in a LIRI animal model. This study aimed to clarify the role of complement depletion induced by CVF in blood-air barrier during LIRI development. This novel mechanism provides a potential role for complement depletion in LIRI therapeutic applications.

Materials and Methods

Animal Groups. Adult Sprague-Dawley rats (male, 200–250 g) provided by animal experiment center (Guangxi Medical University, China) were randomly assigned to five groups (n = 6): (1) Control group (not treated with anything), (2) Sham-operated group (underwent thoracotomy, not occluded the hilus pulmonis and reperfusion), (3) I/R (lung ischemia-reperfusion) group, (4) CVF group (only injected CVF), (5) I/R + CVF group. The animal experiment protocol was authorized and all animal experiments were carried out in accordance with the guidelines of the Animal Care and Use Ethics Committee (Guangxi Medical University, China).

CVF Application. CVF (catalogue number: ZX0006; Shanghai Heng Fei biological technology CO. LTD, China) purified from the chinese Cobra venom, was dissolved in normal saline (Sichuan Ke Lun Pharmaceutical CO. LTD, China) and injected via the tail vein at 50 μg/kg at 24 h before anesthesia. The usage and dose of CVF were determined according to previous study 17.

Animal model of LIRI. The rat model of LIRI was established as we described previously 18. Rats were anesthetized by 10% chloral hydrate (4.5 ml/kg) through intraperitoneal injection. Tracheal intubation was administrated after anesthesia. RSP1002-type small animal ventilator was applied to mechanical ventilation with breathing frequency of 80 breaths/min, tidal volume of 10 ml/kg, respiratory ratio of 1:1, inspired oxygen concentration of 100%. After underwent thoracotomy, the rats in I/R group were occluded the left hilus pulmonis (including pulmonary bronchi, artery, and vein) by a microvascular clamp for 60 minutes, followed a reperfusion of 120 minutes before closing thoracic incision. The rats in Sham-operated group had undergone thoracotomy, but were not occluded the hilus pulmonis and reperfusion. All rats were sacrificed by cervical vertebra dislocation at 2 h after operation. The left lung tissue, the venous blood, and bronchoalveolar lavage fluid (BALF) were collected. No animal mortality was recorded during the entire experiments.

Evaluation of histological morphology. As we described previously 18, 19, rats lung tissues were fixed in 4% paraformaldehyde and embedded in paraffin. The slices (4 microns) were waxed off by hydration and xylene, stained by Hematoxylin and eosin (H&E). After conventional dehydration, transparency and sealing, stained paraffin sections were examined by light microscopy. 10 fields were examined at 200 × total magnification for each section. The damage of lung tissue was assessed with a scoring system as described previously 6. Briefly, the first standard for evaluation was aggregation or infiltration of inflammatory cells in vessel wall or air space: 1 = only...
wall and air space, 2 = few cells infiltration in air space, 3 = intermediate, 4 = severe aggregation of inflammatory cells in air space. Second standard for evaluation was hyaline membrane formation and interstitial congestion: 1 = normal, 2 = moderate (>25% of lung section), 3 = intermediate (25%–50% of lung section), 4 = severe (>50% of lung section). Third standard for evaluation was hemorrhage: 0 = absent, 1 = present. Sections were prepared and examined by experienced pathologists who were blinded to the group assignment.

Collection of BALF. BALF was isolated as we described previously. Briefly, 5 ml of cold phosphate buffered saline (Dulbecco’s PBS; Gibco BRL, Grand Island, USA) were flushed to the lungs through the cannulated trachea to collect BALF.

Determination of complement activity. CVF is a stable anti-complement protein and functionally resembles C3 purified from Cobra venom. To testify complement depletion induced by CVF pretreatment, complement activities were determined by the 50% haemolytic complement (CH50) activity in serum and the C3 level in the plasma and BALF. The CH50 is a screening assay which can test the functional capability of serum complement components. The level of CH50 in serum was determined by hemolytic assay. In brief, serum samples were sensitized with goat anti-serum and incubated at 30 °C for 60 min to serial dilutions in gelatin veronal buffer (Sigma, St. Louis, MO, USA). After a centrifugation step (2500 g, 5 min), the supernatant fluid was collected and measured at 405 nm. The C3 levels in the plasma and BALF were determined by ELISA (catalogue number: ab157731; Abcam, Cambridge, MA) according to the manufacturer’s instructions. The quantity of C3 was standardized to a predetermined standard quantity derived from SD rat.

Inflammatory Cytokines Measurements in Lung tissues and BALF. ELISA kits for measuring rat IL-1β, IL-6 and TNF-α (catalogue number: RLB00, R6000B and RTA00, respectively; R&D Systems, USA) were used to measure the contents of IL-1β, IL-6 and TNF-α in lung tissues and BALF according to the manufacturer’s instructions. The quantity of the cytokine was standardized to the protein content. MPO (myeloperoxidase) is a lysosomal protein stored and abundantly expressed in the neutrophils. Therefore, we determined MPO activity in lung tissues and BALF to evaluate the neutrophils infiltration. MPO activity was measured with chemical method according to the manufacturer’s instructions (Nanjing Jiancheng Biochemistry Co., Nanjing, China).

Determination of wet/dry ratio. As we described previously, wet/dry ratios of lung tissues were determined to assess the levels of pulmonary edema and congestion. After rats were sacrificed, the lower lobe tissues of left lung were immediately weighed, then the tissues were weighted again after dried at 60 °C for 24 h.

Determination of Pulmonary Microvascular Permeability. The total protein in BALF could indicate the permeability of alveolar vascular. Total protein in BALF was measured by the bicinchoninic acid (BCA) assay according to the manufacturer’s instructions (Pierce, Rockford, USA).
Western Blot Analysis. As we described previously, the left lung tissues (50 ug) were homogenized in RIPA buffer (catalogue number: 89900; Thermo Scientific, USA) containing phosphatase inhibitor cocktail (catalogue number: 04906845001; Roche Applied Science, USA) and protease inhibitor cocktail (catalogue number: P2714; Sigma, USA). Homogenates were centrifuged at 4 °C (13,000 rpm, 20 min). The supernatant was absorbed as the total protein. The protein concentration was measured by BCA protein assay according to the manufacturer’s instructions (catalogue number: 23227; Pierce Biotecnology, USA). Twenty microgram proteins each lane were loaded on a polyacrylamide gel and transferred onto polyvinylidene difluoride membrane. Then the proteins in membrane were incubated with the primary antibodies at 4 °C: anti-AQP1 antibody (1:1000, catalogue number: ab168387; Abcam, USA), anti-ICAM-1 antibody (1:1000, catalogue number: ab206398; Abcam, USA), anti-ZO-1 antibody (1:1000, catalogue number: ab190085; Abcam, USA), anti-MMP2 antibody(1:1000, catalogue number: ab37150; Abcam, USA), anti-MMP9 antibody(1:1000, catalogue number: ab38898; Abcam, USA), anti-β-Actin antibody (1:5000, catalogue number: ab50591; Abcam, USA). The protein bands were developed by enhanced chemiluminescence (Pierce, USA). The intensities of AQP1, ICAM-1, ZO-1, MMP2, MMP9 proteins were normalized by those of β-Actin.

Statistical analysis. All data are presented as the mean ± standard deviation (SD). (n = 6). Statistical analysis were performed using SigmaStat (Systat Software, CA, USA). The data were conducted by one-way analysis of variance followed by the Tukey test if the data were normally distributed or by one-way analysis of variance on ranks followed by the Tukey test if the data were not normally distributed. Differences were considered statistically significant at P < 0.05 based on two-tailed hypothesis testing.

Results CVF induces complement depletion. The levels of CH50 in serum and C3 in plasma and BALF were measured to assess the complement activity. Figure 1A presented the levels of CH50 in serum, Fig. 1B presented the levels of C3 in plasma, Fig. 1C presented the levels of C3 in BALF. The results demonstrated that CVF significantly reduced complement activity and could induce complement depletion in a rat model (P < 0.05).
CVF pretreatment ameliorates LIRI in morphology. Lung tissue staining and histology scoring were conducted to assess lung injury by I/R. Figure 2A showed the pulmonary morphology of all groups. The structures of lung tissues were intact, rarely inflammatory cells and red blood cells infiltration in control, sham and CVF groups. No difference was noted between control, Sham and CVF group \((P > 0.05)\) (Fig. 2B). In I/R group, the alveolar septum had been ruptured, lung tissue structures were ambiguous, a large number of inflammatory cells and red blood cells infiltration were observed. The lung injury score was significantly higher in I/R group compared with the control group \((P < 0.05)\). In I/R + CVF group, lung tissue structures were roughly intact, a small number of red blood cells and neutrophils had infiltrated into the alveolar space. Lung tissue damage was significantly alleviated in I/R + CVF group compared with I/R group \((P < 0.05)\).

CVF pretreatment inhibits inflammatory response in IR condition. IL-1\(\beta\), IL-6, TNF-\(\alpha\) and MPO were determined to assess the inflammatory response in lung tissues and BALF (Fig. 3). The results showed that compared with the control group, the expression of IL-1\(\beta\), IL-6, TNF-\(\alpha\) and MPO in Lung tissues and BALF significantly increased in I/R group \((P < 0.05)\). Compared with the I/R group, CVF pretreatment significantly inhibited the expression of IL-1\(\beta\), IL-6, TNF-\(\alpha\) and MPO induced by lung I/R \((P < 0.05)\).

CVF pretreatment decreases pulmonary permeability and edema in IR condition. Pulmonary wet/dry ratios, the total proteins in BALF, and the expression of AQP1 in lung tissues were measured to evaluate pulmonary permeability and edema. The wet/dry ratios in lung tissues were showed in Fig. 4A, the levels of total proteins in BALF were showed in Fig. 4B–D presented the expression of AQP1 in lung tissues. Compared with the control group, lung I/R significantly increased the wet/dry ratios, the expression of total proteins in BALF and AQP1 in lung tissues \((P < 0.05)\). Compared with the I/R group, pretreatment with CVF significantly reduced the wet/dry ratios, the total proteins in BALF and the AQP1 expression in lung tissues \((P < 0.05)\).

Function of CVF in preserving integrity of tight junctions and blood-air barrier in IR condition. The protein expression of ICAM-1, ZO-1, MMP2, MMP9 in Lung tissues were measured by Western Blot Analysis to assess the integrity of tight junctions and blood-air barrier. The results in Fig. 5A,B showed that compared with the control group, the expression of ICAM-1 in lung tissues was significantly increased after lung I/R \((P < 0.05)\). CVF pretreatment significantly inhibited the ICAM-1 expression induced by lung I/R \((P < 0.05)\). The results in Fig. 5C,D demonstrated that compared with the control group, lung I/R had significantly reduced the expression of ZO-1 in lung tissues, and CVF pretreatment significantly increased ZO-1 expression compared with the I/R group \((P < 0.05)\). Figure 5E–H showed that the expression of MMP2 and MMP9 in lung tissues significantly increased in I/R group compared with the control group \((P < 0.05)\). CVF pretreatment significantly inhibited the I/R-induced MMP2 and MMP9 expression \((P < 0.05)\). The results demonstrated that pretreatment with CVF had the function of preserving integrity of tight junctions and blood-air barrier in I/R condition.
Discussion

During the occurring and developing progressions of the diseases, complement system is activated producing some pivotal complement components such as C3 and C521–23. More and more studies have indicated that the excessive complement activation is intimately related to the initiation and amplification of the organs and tissues injury caused by I/R24–27. Consistent with the previous reports, our study showed that the levels of CH50 in plasma and C3 in plasma and BALF significantly enhanced after lung I/R. CVF is a structural and functional analogue of complement component C313, which can cause continuously and excessively activation of C3 resulting in complement components depletion in serum. In this study, pretreatment with CVF significantly reduced the expression of complement component in plasma and BALF, which demonstrated complement depletion induced by CVF in a rat model.

The complement system plays a pivotal role in activating the innate immunity. However, overwhelming activation of complement has a close relationship with excessive immune activation and inflammatory eruption resulting in severe tissue injury. Some previous studies showed that the process of I/R initiated a complement activation and inflammatory response, which accompanied with releasing complement component and pro-inflammatory factors, attracting inflammatory cells and lysosomal enzymes, increasing small vasodilatation and pulmonary vascular permeability28. In this study, we found that after lung I/R, lung injury was obvious in morphology, the alveolar septums were ruptured, lung tissue structures were ambiguous, a large number of red blood cells and inflammatory cells infiltration were observed. Pretreatment with CVF could significantly ameliorate the damage of lung tissues induced by lung I/R. This effects of CVF pretreatment were consistent with the previous reports24–27. Our results revealed that complement depletion induced by CVF pretreatment could reduce the pro-inflammatory factors release and PMN infiltration, which was contributed to relieve the damage of lung.
tissues in the process of lung I/R. The results are consistent with some previous studies. Hu et al. found that autophagy mediated by CsA could induce alveolar macrophages apoptosis, disrupted pulmonary homeostasis and contributed to the development of ALI in a intestinal I/R mouse model. Mao et al. have suggested that CVF could significantly reduce lung tissues damage caused by I/R, the mechanism might be inhibition of oxidant generation, infiltration of neutrophils. Proctor et al. found that complement inhibitors could selectively attenuate tissues injury following administration of CVF to rats. But some studies have the opposite conclusion. Glasgow et al. found that complement depletion induced by preoperative administration of CVF resulted in increased pulmonary inflammation following liver cryo injury via relative upregulation of NF-kappaB activity.

To assess pulmonary permeability and edema, we measured pulmonary wet/dry ratios, the expression of total proteins in BALF and AQP1 in lung tissues. Our results were as anticipated, that CVF pretreatment significantly reduced the wet/dry ratios, the levels of total proteins in BALF and AQP1 expression after lung IR. This result was consistent with the result of the pathological morphology.

Furthermore, to assess the integrity of blood-air barrier, we evaluated the effect of CVF pretreatment on the ICAM-1, ZO-1, MMP2, MMP9 protein expression in Lung tissues. ICAM-1 is an endothelial-associated trans-membrane protein, and has an important role in stabilizing cell-cell interactions. ICAM-1 expression can significantly increase caused by tissues injury32. ZO-1 is one of the essential members in composing intact cell tight junctions which is vital to maintain the integrity of microvascular barrier33. The main function of MMP2 and MMP9 is to degrade and restore the extracellular matrix and maintain the dynamic balance in basement membrane. MMP2 and MMP9 can destroy the basement membrane and promote inflammation, play an important role in reconstruction extracellular matrix in the process of tissues injury34. In this study, ICAM-1, MMP2, MMP9 significantly increased and ZO-1 significantly reduced in lung I/R rat animals, pretreatment with CVF can change the expressions of ICAM-1, ZO-1, MMP2, MMP9. The results suggested that lung I/R can lead to severe damage of blood-air barrier, and CVF pretreatment had the function of preserving integrity of tight junctions and blood-air barrier in I/R condition.

In this study, our data indicated illustrated that complement activation play an important role in the pathological process of LIRI, complement depletion induced by CVF pretreatment might be an option to prevent and cure tissue injury caused by I/R. However, Some conditions still restrict the use of CVF in clinical practice. For example, complement depletion by CVF can decrease the immune function, CVF affects all organs of the body and cannot aim at the injured organ. More innovative studies are needed if we want to realize the use of CVF in clinical condition.

Conclusion
We come to the conclusion that CVF pretreatment could ameliorate LIRI and inhibit I/R-induced inflammatory response. The mechanisms of its protective effects might be alleviated blood-air barrier damage.

References
1. Fiser, S. M. et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 73, 1041–1048 (2002).
2. Eltzschig, H. K., Bratton, D. L. & Colgan, S. P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov 13, 852–869 (2014).
3. den Hengst, W. A. et al. Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol 299, H1283–H1299 (2010).
4. de Perrot, M. et al. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167, 490–511 (2003).
5. Lin, Q. et al. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases. Int Immunopharmacol 11, 1422–1432 (2011).
6. Arun Prakash, S. V. et al. Lung ischemia–reperfusion is a sterile inflammatory process influenced by commensal microbiota in mice. Shock 44, 272–279 (2015).
7. Zhu, Q. et al. Protective effects of fenofibrate against acute lung injury induced by intestinal ischemia/reperfusion in mice. Sci Rep. 23, 22044 (2016).
8. Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion–from mechanism to translation. Nat Med 17, 1391–1401 (2011).
9. Diepenhorst, G. M., van Gulik, T. M. & Hack, C. E. Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 249, 889–899 (2009).
10. Arumugam, T. V. et al. The role of the complement system in ischemia–reperfusion injury. Shock 21, 401–409 (2004).
11. Chen, J. et al. A novel inhibitor of the alternative pathway of complement attenuates intestinal ischemia reperfusion induced injury. J Surg Res 167, e131–e136 (2011).
12. Weeks, C. et al. Decay-accelerating factor attenuates remote ischemia reperfusion initiated organ damage. Clin Immunol 124, 311–327 (2007).
13. Kock, M. A. et al. Structure and function of recombinant cobra venom factor. J Biol Chem 279, 30836–30843 (2004).
14. Vogel, C. W. & Fritzinger, D. C. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 56, 1198–1222 (2010).
15. Oh, J. Y. et al. Complement depletion with cobra venom factor delays acute cell-mediated rejection in pig-to-mouse corneal xenotransplantation. Xenotransplantation 17, 140–146 (2010).
16. Shen, S. S. et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 11, 2057–2066 (2011).
17. Mao, Y. F. et al. Pretreatment with Cobra venom factor alleviates acute lung injury induced by intestinal ischemia-reperfusion in rats. Eur Rev Med Pharmacol Sci 17, 2207–2217 (2013).
18. Lin, F. et al. Glycyrrhizin ameliorate ischemia reperfusion lung injury through downregulate TLR2 signaling cascade in alveolar macrophages. Front Pharmacol 8, 389 (2017).
19. Lin, F. et al. Differential expression of HIF-1alpha, AQP-1, and VEGF under acute hypoxic conditions in the non-ventilated lung of a one-lung ventilation rat model. Life Sci 124, 50–55 (2015).
20. Dai, H. et al. Mechanical ventilation modulates Toll-like receptors 2, 4, and 9 on alveolar macrophages in a ventilator-induced lung injury model. J Thorac Dis 7, 616–624 (2015).
21. Acosta, J., Qin, X. & Halperin, J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 10, 203–211 (2004).
22. Bosmann, M. & Ward, P. A. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. *Adv Exp Med Biol* **946**, 147–159 (2012).

23. Strainic, M. G. et al. Absence of signaling into CD4(+) cells via C3αR and C5αR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. *Nat Immunol* **14**, 162–171 (2013).

24. Gorsuch, W. B. et al. The complement system in ischemia-reperfusion injuries. *Immunobiol* **217**, 1026–1033 (2012).

25. Ricklin, D. et al. Complement: a key system for immune surveillance and homeostasis. *Nat Immunol* **11**, 785–797 (2010).

26. Farrar, C. A. et al. Which pathways trigger the role of complement in ischaemia/reperfusion injury? *Front Immunol* **3**, 341 (2012).

27. Kambas, K. et al. C5a and TNF-α up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. *J Immunol* **180**, 7368–7375 (2008).

28. Harkin, D. W. et al. C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm. *Br J Surg* **92**, 1227–1234 (2005).

29. Hu, R. et al. Complement C5a exacerbates acute lung injury induced through autophagy-mediated alveolarmacrophage apoptosis. *Cell Death Dis* **9**, e1330 (2014).

30. Proctor, L. M. et al. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. *Int Immunopharmacol* **6**, 1224–1232 (2006).

31. Glasgow, S. C. et al. Complement depletion enhances pulmonary inflammatory response after liver injury. *J Gastrointest Surg* **10**, 357–364 (2006).

32. Hayashi, K. et al. A novel inhibitory mechanism of MRTF-A/B on the ICAM-1 gene expression in vascular endothelial cells. *Sci Rep* **9**, 10627 (2015).

33. Tornavaca, O. et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. *J Cell Biol* **208**, 821–838 (2015).

34. Carneiro, P. J. et al. Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis. *Front Physiol* **8**, 159 (2017).

Acknowledgements

The following grants and foundations supported this work: Research grant No. 81560018 from the National Natural Science Foundation of China, Research grant No. S201418-05 from the Bureau of Health, Guangxi, Research grant No. GXMUYSP201305 from Guangxi medical university.

Author Contributions

Chang Haihua: Study design, fund collection, samples detection, manuscript preparation. Wang Wei: Data interpretation, samples detection, literature search. Huang Kun: Data collection, animal model. Liao Yuanli: Statistical analysis. Lin Fei: Study design, fund collection, manuscript preparation.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018